4.8 Review

CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors

Journal

CELL
Volume 181, Issue 1, Pages 136-150

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2020.03.023

Keywords

-

Funding

  1. Pitt Hopkins Research Foundation
  2. Grace Science Foundation
  3. NIH [1R01-HG009761, 1R01-MH110049, 1DP1-HL141201, 5R-M1HG006193-09]
  4. Howard Hughes Medical Institute
  5. Harold G. and Leila Mathers, Jr. Foundation
  6. Edward Mallinckrodt, Jr. Foundation
  7. Poitras Center for Psychiatric Disorders Research
  8. Hock E. Tan and K. Lisa Yang Center for Autism Research at MIT
  9. Open Philanthropy Project, the Phillips family
  10. NIH
  11. Cystic Fibrosis Foundation
  12. Michelson Found Animals Foundation
  13. Believe in a Cure

Ask authors/readers for more resources

The development of clustered regularly interspaced short-palindromic repeat (CRISPR)-based biotechnologies has revolutionized the life sciences and introduced new therapeutic modalities with the potential to treat a wide range of diseases. Here, we describe CRISPR-based strategies to improve human health, with an emphasis on the delivery of CRISPR therapeutics directly into the human body using adeno-associated virus (AAV) vectors. We also discuss challenges facing broad deployment of CRISPR-based therapeutics and highlight areas where continued discovery and technological development can further advance these revolutionary new treatments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available